ACAD
31.77
-0.8
-2.46%
AEMD
0.26
+0.01
+2.00%
APRI
1.22
-0.02
-1.61%
ARNA
4.52
-0.14
-3.00%
ATEC
1.36
+0.01
+0.74%
CFN
59.75
-0.23
-0.38%
CNAT
5.34
+0.02
+0.38%
CRXM
0.2
+0.02
+11.11%
CYTX
0.47
-0.01
-1.19%
DXCM
57.92
-0.19
-0.33%
GNMK
13.18
+0.09
+0.69%
HALO
13.89
-0.12
-0.86%
ILMN
196.69
+2.8
+1.44%
INNV
0.25
+0.01
+4.17%
INO
8.62
+0.12
+1.41%
ISCO
0.06
0.00
0.00%
ISIS
71.25
+0.27
+0.37%
LGND
54.86
-0.97
-1.74%
LPTN
2.97
0.00
0.00%
MBVX
1.1
-0.15
-12.00%
MEIP
3.69
-0.1
-2.64%
MNOV
3.52
-0.12
-3.17%
MRTX
19.27
-0.15
-0.77%
MSTX
0.48
+0.00
+0.04%
NBIX
31.71
+0.13
+0.41%
NUVA
46.93
-0.26
-0.55%
ONCS
0.4
+0.00
+0.25%
ONVO
6.32
-0.05
-0.78%
OREX
5.4
+0.12
+2.27%
OTIC
32.83
+3.49
+11.90%
QDEL
24.26
-0.04
-0.16%
RCPT
110.23
+3.01
+2.80%
RGLS
18.53
+0.27
+1.48%
RMD
65.44
+3.58
+5.79%
SCIE
0.01
0.00
-7.75%
SPHS
0.45
+0.00
+1.02%
SRNE
9.96
-0.03
-0.30%
TROV
5.82
0.00
-0.06%
VICL
1.04
+0.01
+0.96%
VOLC
17.96
+0.01
+0.06%
ZGNX
1.34
+0.05
+3.88%
Home » Archive by Category

Drug Discovery

San Diego’s Antibody-Drug Conjugate Research Highlighted at #WorldADC Meeting in October

November 24, 2014 – 8:11 am | Edit Post

San Diego was host to the World Antibody Drug Conjugate (ADC) Meeting and Awards October 26-29th 2014. ADCs are an exciting new class of oncology therapeutics utilizing monoclonal antibodies conjugated to cytotoxic drugs, resulting in …

SDBN August 21st 2012 Event At The Sanford Consortium For Regenerative Medicine

August 3, 2012 – 12:41 pm | Edit Post

The Sanford Consortium for Regenerative Medicine is a stem cell research facility representing a collaboration between five of San Diego’s finest research institutions: Sanford-Burnham Medical Research Institute, The Salk Institute, The Scripps Research Institute and …

SDBN June 25th Event With Lilly: Open Innovation Drug Discovery

June 4, 2012 – 1:48 am | Edit Post

San Diego biotech has grown thanks to a collaborative spirit which is sometimes manifested in the acquisition and joining of companies towards a common goal. Lilly’s presence here is indicative of this type of growth, …

San Diego’s Biotechnology Companies: Who’s Taking Off?

March 8, 2012 – 9:13 am | Edit Post

Here at SDBN we’ve been updating our directory of 400+ San Diego biotech companies.  We were surprised to find close to 40 companies removed from the local scene – due to acquisition or shut down.  …

SDBN March 26th 2012 Event with Organovo

March 6, 2012 – 1:59 pm | Edit Post

Organovo is an exciting San Diego biotech company with technology to create human tissue through a technique called 3D bioprinting. The tissue can be used for drug discovery and development, and the company has been …

Focus on San Diego: Life Science Conferences Spring 2012

January 31, 2012 – 11:56 am | Edit Post

This spring San Diego downtown will be buzzing with scientific discussions as our city hosts a number of major scientific symposia.  We are excited to attend and soak in all the science that will be …

Virtual Biotech Part 1: What We Learned About Effectively Outsourcing a Drug Discovery Program

July 28, 2011 – 12:04 pm | Edit Post
virtual drug discovery SDBN Event

The first in our Virtual Biotech series, our July 19th event was a success.  Thanks to our participants – some of San Diego’s leading virtual drug discovery scientists and CROs – for sharing their valuable …

SDBN July 19th Event: Virtual Biotech Part 1: How to Effectively Outsource a Drug Discovery Program

July 1, 2011 – 3:47 pm | Edit Post

Changes in the drug discovery landscape have presented many tough challenges for our region, including downsizing for larger companies and a dearth of VC funding for startups. With these challenges come opportunities, however, because drug …

SDBN June 21st Event Featuring aTyr Pharma

May 27, 2011 – 9:58 am | Edit Post

The San Diego Biotechnology Network’s June 21st event will feature aTyr Pharma, with Board Member and CEO Jeffry Watkins (Bio) giving a talk titled “Innovation: Where is our Biology?” aTyr is developing therapeutics based on …

SDBN April 19th 2011 Event Featuring Celgene

March 22, 2011 – 6:15 pm | Edit Post

Through research, acquisitions, and mergers, Celgene has built a robust product portfolio and pipeline in hematology and oncology. This accomplishment is quite a feat in today’s environment, with pharma pipelines dwindling, and they are one …